BNP Paribas Asset Management
APLS

BNP Paribas Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

BNP Paribas Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,100
Closed -$44.3K – 2266
2026
Q1 		$44.3K Buy
1,100
+260
+31% +$5.6K ﹤0.01% 1788
2025
Q4 		$21K Buy
840
+246
+41% +$5.77K ﹤0.01% 1939
2025
Q3 		$13K Hold
594
– – ﹤0.01% 1538
2025
Q2 		$10K Buy
+594
New +$11K ﹤0.01% 1757

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BNP Paribas Asset Management's APLS Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,100 shares — an estimated $44.3K sold.

BNP Paribas Asset Management first reported a position in APLS in Q2 2025 and held it in 4 quarters. The position peaked at $44.3K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 1,100 Apellis Pharmaceuticals shares in Q2 2026, an estimated $44.3K.
  • BNP Paribas Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • BNP Paribas Asset Management's Apellis Pharmaceuticals position peaked at $44.3K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.